Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) granted inducement equity awards to thirteen new employees on July 1, 2026, under its 2024 Inducement Plan.

The awards comprise time-based restricted stock units for an aggregate of 53,250 common shares, vesting in three equal annual installments, subject to continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – NTLA

-2.30%

9 alerts

-2.30% Session close to close

-3.6% Trough in 12 min

$2.45B Market Cap

0.1x Rel. Volume

In the Jul 7 session, NTLA declined 2.30%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.6% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The filing adds incremental detail on new-hire inducement RSUs under the 2024 plan, a routine compen...

Analysis

The filing adds incremental detail on new-hire inducement RSUs under the 2024 plan, a routine compensation practice. Prior similar grants have produced mixed price reactions, so investors may focus more on high short positioning and upcoming clinical or regulatory milestones than on this announcement alone.

Key Figures

Inducement grant date: July 1, 2026 New employees: 13 employees Inducement plan year: 2024 Inducement Plan +3 more

6 metrics

Inducement grant date July 1, 2026 Grant date for new employee equity awards

New employees 13 employees Recipients of inducement equity grants

Inducement plan year 2024 Inducement Plan Plan under which awards were granted

RSU shares 53,250 shares Aggregate time-based RSUs granted as inducement awards

Vesting duration 3 years RSUs vesting period for inducement awards

Annual vesting rate One-third per year Proportion of RSUs vesting each year

Historical Context

5 past events · Latest: Jun 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 05	Inducement grants	Neutral	+0.1%	Small inducement RSU grants produced minimal next-day share price reaction.
Jun 01	Clinical data update	Positive	-2.4%	Upcoming additional Phase 3 lonvo-z data announcement coincided with a share price decline.
May 11	Earnings and pipeline	Positive	+2.3%	Q1 2026 results and positive late-stage data saw a modest positive price move.
May 05	Investor conferences	Neutral	-4.0%	Investor conference participation news was followed by a notable share price drop.
May 01	Inducement grants	Neutral	+4.6%	Larger prior inducement RSU grants coincided with a strong positive price reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Over recent months, NTLA’s stock has sometimes moved sharply on neutral items while generally aligning with directionally positive clinical and earnings updates.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), equity incentive plans, inducement plan

4 terms

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity incentive plans financial

"granted outside of Intellia’s stockholder-approved equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

inducement plan financial

"under Intellia’s 2024 Inducement Plan, as amended"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 53,250 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

FAQ

What inducement grants did Intellia Therapeutics (NTLA) approve on July 1, 2026?

Intellia granted time-based RSUs covering an aggregate of 53,250 common shares to thirteen new employees. According to Intellia, these awards were issued under its 2024 Inducement Plan as a material inducement to employment.

How do the new Intellia Therapeutics (NTLA) inducement RSUs vest for employees?

The inducement RSUs vest in three equal annual installments over three years. According to Intellia, vesting for each employee depends on continued service as an employee or other service provider through the applicable vesting dates.

Under which plan were the July 2026 Intellia Therapeutics (NTLA) inducement awards granted?

The awards were granted under Intellia’s 2024 Inducement Plan, as amended. According to Intellia, this plan was initially adopted by the board of directors in June 2024 and operates outside stockholder-approved equity incentive plans.

How does Nasdaq Listing Rule 5635(c)(4) relate to Intellia Therapeutics (NTLA) July 2026 grants?

The inducement RSU awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). According to Intellia, they were considered a material inducement to entering employment and were granted outside the company’s stockholder-approved equity plans.

How many employees received Intellia Therapeutics (NTLA) inducement RSUs in July 2026?

Thirteen new employees received RSU inducement grants on July 1, 2026. According to Intellia, these employees share an aggregate of 53,250 RSUs that vest annually over three years, subject to continued employment or qualifying service.